Xiaofeng Han

Xiaofeng (Kevin) Han has a wealth of work experience in the bioprocess industry. Xiaofeng (Kevin) began their career in 2007 as a Postdoc at the University of Kansas. In 2008, they moved to Oklahoma State University where they worked as a Postdoc and developed a new purification method to get soluble, active MID1 protein by using detergents. In 2010, they became a Postdoc Research Associate at SUNY Upstate Medical University and targeted the cancer-related kinase EphA4. Xiaofeng (Kevin) also established a computer-aided drug design platform for the lab and found some lead compounds with high potent targeting cancer-related protein b-catenin and HIV-infection related GPCR CXCR4 by using virtual screening. In 2012, they joined Wayne State University as a Research Associate. In 2015, they moved to the Eppendorf Group as a Research Scientist, Cell Culture Bioprocess and designed and conducted experiments to validate and support current and new products in cell culture and bioprocess. In 2018, they joined JOINN Biologics US Inc. as the Sr. Director, Process Development & Pilot Production. Xiaofeng (Kevin) also served as the Director, Process Development and provided technical oversight on all upstream process development, process transfer, and training to junior scientists. Xiaofeng (Kevin) established the entire PD upstream lab for the company and provided technical leadership and expert input into developing, optimizing, scaling-up, troubleshooting, and validating all steps in the upstream process development group. Xiaofeng (Kevin) also held the role of Associate Director, Process Development--Upstream, where they had expertise in benchtop bioprocess including Ambr250, Sartorius B-DCU (2L, 10L UniVessel SU/Glass), RM (WAVE) bioreactor, Eppendorf Dasbox, BioFLO320 (3L, 10L, 50L BioBLU vessel), Repligen ATF2 perfusion (N-1stage, N stage), and Depth filtration/clarification (Millipore POD, Sartoclear).

Xiaofeng (Kevin) Han received a Bachelor's Degree from Nankai University between 1996 and 2000. Xiaofeng (Kevin) then went on to pursue a Ph.D in Chemistry and Drug Design from Peking University, which they completed in 2006.